Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in hepatocellular carcinoma after radiological progression
2011-006194-26Phase 4Active
- Sponsor
- JOSE LUIS MONTERO ALVAREZ
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Overall survival. Started Feb 2012; status: active.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-006194-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006194-26.